Valye reports for unlimited access

PDS Biotechnology Corp develops immunotherapies based on its Versamune® T cell activator platform, designed to stimulate potent CD8 and CD4 T cell responses against cancer and infectious diseases. The company’s pipeline includes PDS0101, a Versamune®-based product candidate, and PDS01ADC, an IL-12 fused antibody drug conjugate aimed at enhancing tumor immune response. Clinical programs include Phase 2 and Phase 3 trials targeting HPV16-positive head and neck squamous cell carcinoma and metastatic colorectal cancer. The company relies on third-party manufacturers and maintains a focus on regulatory compliance and intellectual property protection. Financially, PDS Biotechnology has not yet generated product revenue and continues to incur net losses while funding operations through equity and debt financing.

Nuo Therapeutics, Inc. develops and markets the Aurix System, a point-of-care medical device that produces autologous platelet rich plasma gel for the treatment of chronic wounds such as diabetic foot ulcers, leg ulcers, and pressure ulcers. The Aurix System is FDA-cleared and leverages the regenerative capacity of the patient's own blood to promote natural healing. The company operates primarily in the U.S. advanced wound care market, which was estimated at $10.8 billion globally in 2021. After a period of operational pause pending Medicare coverage reconsideration, Nuo resumed commercial activities in late 2021 following a favorable CMS National Coverage Determination. The company has established a network of over 200 sales agents and distributors and entered a distribution agreement with Smith+Nephew for exclusive U.S. distribution of a private label Aurix product. Nuo faces competition from other platelet derived products and advanced wound care therapies, many from larger companies with greater resources. The company reported net losses and limited liquidity as of the end of 2025.

StableX Technologies, Inc. is a publicly traded company on Nasdaq (ticker: SBLX) that has adopted a business strategy centered on investing in digital assets associated with the stablecoin industry. The company focuses on acquiring and holding a diversified portfolio of tokens linked to stablecoin infrastructure, including FLUID, INJ, LINK, AAVE, SYRUP, QNT, and ETHFI. These digital assets are subject to high volatility, liquidity challenges, and regulatory uncertainties. The company’s financial disclosures as of the fiscal year ending December 31, 2025, indicate significant net losses and liquidity positions supported by cash and short-term investments. The company also faces financial obligations related to preferred stock that may impact cash resources. The regulatory and technological environment for digital assets presents ongoing risks that could materially affect the company’s financial condition and operations.

Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies. The company develops genomic tests to personalize medicine and improve diagnosis and management, focusing currently on thyroid cancer tests ThyGeNEXT and ThyraMIR v2 after discontinuing PancraGEN in 2025 due to CMS reimbursement cessation. Customers include physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics, with revenue from Medicare, Medicaid, commercial payers, and direct client billings. The company operates a CLIA-certified and CAP-accredited laboratory in Pittsburgh, Pennsylvania. Its strategy emphasizes organic growth, partnerships, expanding test awareness, improving operational efficiencies, broadening reimbursement coverage, and leveraging bioinformatics. The company competes with larger firms such as Veracyte, Quest Diagnostics, and Sonic Healthcare in the thyroid diagnostic market. Financially, the company reported net income of $24.575 million and basic EPS of $5.55 for fiscal year 2025, with liquidity ratios indicating moderate short-term financial health. The company’s stock is quoted on the OTCID tier following delisting from Nasdaq in 2021.

Spark I Acquisition Corp is a special purpose acquisition company incorporated in the Cayman Islands and listed on Nasdaq. The company’s primary purpose is to identify and complete a business combination, with a current focus on a potential transaction with Kneron Holding Corporation, a provider of edge artificial intelligence solutions. The company has extended its deadline to consummate a business combination to September 29, 2026, subject to shareholder approval. Financially, the company holds limited cash and assets relative to its liabilities, reflecting its SPAC status prior to completing a business combination. It has arrangements with its sponsor to receive funding through promissory notes to support working capital needs until a business combination is completed.

Dragonfly Energy Holdings Corp. designs, manufactures, and sells lithium iron phosphate (LFP) batteries and integrated energy storage systems primarily for the recreational vehicle (RV), marine, industrial, and trucking markets. The company leverages proprietary dry-electrode manufacturing technology and is developing solid-state battery technology to enhance safety and performance. Its products are marketed under the Battle Born brand, which includes battery packs with integrated management systems and heating capabilities for cold climates. Dragonfly Energy has shifted its growth focus from direct-to-consumer sales toward OEM, fleet, and industrial channels, with significant OEM partnerships in the RV industry and expanding presence in heavy-duty trucking. The company operates a large manufacturing facility in Reno, Nevada, and sources key battery components from select suppliers. It also holds a substantial patent portfolio supporting its technology and manufacturing processes.

Yale Transaction Finders, Inc. was originally incorporated in 2000 and has undergone several name changes. It previously operated an online yacht database but discontinued that business in 2007. Since then, it has operated as a shell company focused on identifying and acquiring a target business through a business combination. The company has no current operations, employees, or revenue, and its financial condition reflects ongoing losses and negative working capital. Its acquisition search is unrestricted by geography or industry, with management discretion to select candidates. The company faces competition from more experienced and better-resourced entities in locating acquisition targets.

Avenue Therapeutics, Inc. operates as a specialty pharmaceutical company focused on developing and commercializing therapies for neurologic diseases. Its primary product candidate is intravenous tramadol, intended for treatment of post-operative acute pain. The company previously developed AJ201 for spinal and bulbar muscular atrophy under a license agreement with AnnJi Pharmaceutical, which was terminated in April 2025. Avenue recognized revenue related to this license termination and has reduced research and development expenses accordingly. The company sold its BAER-101 asset in November 2025. Avenue's common stock was delisted from Nasdaq in 2025 and now trades on the OTC market. The company funds operations primarily through equity offerings and maintains liquidity to support clinical development and regulatory activities. It operates in a single reportable segment encompassing all development and commercialization activities.

AmBase Corporation operates as a holding company with a focus on managing its assets and liabilities. Its primary asset is cash and cash equivalents, with a significant equity investment in a real estate development property located at 111 West 57th Street in New York City. This investment is involved in material legal disputes and has been fully impaired. The company has a history of operating losses and limited operational activity, with a small number of employees. AmBase is engaged in ongoing litigation related to its real estate investment and is exploring various strategic alternatives to raise capital, including litigation funding agreements and debt or equity offerings. The company faces risks related to its concentrated real estate investment, competitive pressures in the real estate market, and the illiquidity of its assets.

STRATS Trust for Dominion Resources, Inc. Securities, Series 2005-6 (ticker GJP) is a trust formed to issue certificates backed by securities of Dominion Resources, Inc. The trust was established under a Base Trust Agreement in 2003 and a Series Supplement in 2005. It is managed by Synthetic Fixed-Income Securities, Inc. as depositor and U.S. Bank Trust National Association as trustee. The certificates trade on the New York Stock Exchange. The trust makes periodic distributions to certificate holders, with distribution details filed in SEC current reports. The trust does not prepare or verify the underlying issuer's financial disclosures and does not provide detailed business or financial information in its own filings.

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing innovative opioid prodrug technologies to address severe pain relief while mitigating risks of opioid misuse, abuse, and overdose. The company’s proprietary platforms include the TAAP technology, which activates drugs only in the gastrointestinal tract via trypsin enzyme exposure, and the MPAR® technology, which combines TAAP prodrugs with a trypsin inhibitor to provide overdose protection. Its lead product candidate, PF614, is a delayed-release oxycodone prodrug designed to resist multiple modes of abuse, including oral, nasal, and injection routes. PF614 has undergone multiple Phase 1 and Phase 1b clinical trials, demonstrating safety, pharmacokinetics, and bioequivalence to OxyContin. A pivotal Phase 3 trial for PF614 commenced in mid-2025. The combination product PF614-MPAR has received FDA Breakthrough Therapy designation and is in ongoing clinical evaluation. Ensysce relies on contract manufacturing organizations for production and has sufficient clinical supplies. The company has no approved commercial products and has incurred losses since inception, with financial resources sufficient into the second quarter of 2026. It maintains a small workforce primarily composed of scientific personnel.

Kraig Biocraft Laboratories, Inc. is a smaller reporting company under SEC definitions. The company has limited publicly disclosed information regarding its business model, industry classification, and operations. The latest available financial data from SEC filings shows no recent revenue and a net loss for the fiscal year ended December 31, 2025. Liquidity metrics indicate the company faces significant current liabilities relative to its current assets. The company is not currently involved in any material legal proceedings. Risk factors are not detailed in recent filings but are available in prior public documents and on the company website [S1][S2].

TriLinc Global Impact Fund LLC is an investment fund that provides capital primarily through senior secured term loans and trade finance participations to a diversified portfolio of companies across multiple industries and countries. The fund's portfolio includes investments in sectors such as sustainable packaging, commodities, cocoa processing, chemicals distribution, waste-to-fuels processing, and various service and manufacturing industries. The fund holds multiple classes of capital units and reports detailed financial and portfolio information in its SEC filings. Its investment approach includes valuation methods tailored to credit risk and restructuring status, with active management of Watch List investments. The fund's governance includes a board of managers and an Investment Risk Team overseeing risk management, including cybersecurity.

Myseum, Inc. is a technology company specializing in privacy-focused social media and messaging platforms. Its flagship offerings include Picture Party by Myseum, a social networking platform launched in December 2025 designed for private and controlled sharing of photos, videos, and messages, and the Myseum social media platform launched in March 2025, which enables secure storage and sharing of digital content within private family libraries. The company also operates DatChat Messenger & Private Social Network, which provides enhanced privacy features such as message lifespan control, screenshot prevention, encrypted messaging, and encrypted live video chat. Myseum acquired RPM Interactive, an AI-driven publishing company, through its subsidiary Dragon Interact in 2024 but reduced its ownership stake in 2025. The company emphasizes proprietary technology and holds multiple patents related to encryption and blockchain. It offers its applications for free with plans to monetize via in-app purchases and subscription services. Myseum faces intense competition from established social media and messaging platforms and operates with a small team supplemented by external consultants [S1].

IM Cannabis Corp. is a multinational medical cannabis company incorporated in Canada with principal executive offices in Israel. It operates through subsidiaries in Israel and Germany, focusing on the importation, distribution, and sale of medical cannabis products to patients. In Israel, the company operates licensed pharmacies and online platforms, supplying medical cannabis products sourced from Canadian suppliers and third-party cultivators. In Germany, operations are conducted through Adjupharm GmbH, which holds EU-GMP certifications and licenses for repackaging and distribution. The company completed a 6-for-1 share consolidation in 2024 and acquired full ownership of Focus Medical Herbs Ltd. in 2025. It ceased Canadian operations following restructuring proceedings. IM Cannabis has credit facilities to support working capital and has raised capital through note purchase agreements. The company is navigating regulatory reforms and market challenges in its key geographies and is exploring expansion into the U.S. market.

TIM S.A. operates as a major telecommunications company in Brazil, providing mobile and fixed broadband services. The company has achieved full 4G coverage of Brazil's urban population and all cities, and has rolled out 5G standalone network coverage in all state capitals and over a thousand cities. TIM's network infrastructure includes a large optical fiber backbone and thousands of fiber-connected towers. The company has embraced network virtualization and cloud technologies to improve efficiency and reduce costs. TIM also engages in network sharing agreements with competitors to optimize infrastructure use and reduce capital expenditures. The company supports extensive international roaming services. Financially, TIM reported revenues of BRL 26.6 billion and net income of BRL 4.3 billion for fiscal year 2025, with liquidity ratios reflecting a current ratio below 1.0 and a cash ratio of 0.39 as of year-end 2025 [S1].

Aspen Insurance Holdings Ltd operates as a holding company in the global insurance and reinsurance markets, providing a range of specialty insurance products including financial and professional lines, casualty and liability, specialty, and first-party insurance. The company leverages multiple platforms across the United States, United Kingdom, Bermuda, and Lloyd's of London to offer tailored risk solutions. Aspen also manages alternative reinsurance platforms through its ACM business, which contributes fee income and third-party capital. The company maintains a strong focus on underwriting discipline, capital management, and regulatory compliance across its operating subsidiaries. Aspen's investment portfolio is diversified and primarily investment grade, supporting its underwriting activities and financial strength. The company faces industry risks including competition, regulatory changes, climate change impacts, and cybersecurity challenges.

Costamare Bulkers Holdings Ltd is a holding company focused on the ownership and operation of dry bulk vessels, which are ocean-going ships of 28,000 deadweight tons or more designed to transport unpackaged dry bulk cargo. The company generates revenue primarily through time-charter and voyage charter agreements, recognizing revenue over the term of the charter or evenly over the voyage duration. The vessels are depreciated on a straight-line basis over an estimated useful life of 25 years. The company completed a spin-off and began trading on the NYSE under the ticker CMDB in May 2025. As of the end of 2025, the company had issued approximately 24.4 million common shares and a small number of Series B Preferred Stock shares. The company maintains liquidity with over $211 million in cash and equivalents and a current ratio of 2.38. It operates under a classified board structure with staggered director terms and has established restrictive covenants with major shareholders to manage related party transactions and vessel ownership.

iTonic Holdings Ltd is a Cayman Islands-incorporated company with principal offices in Beijing, China. It files annual reports on Form 20-F with the SEC and has recently undergone a corporate rebranding from Pheton Holdings Ltd to iTonic Holdings Ltd, including a Nasdaq ticker change to ITOC. The company reported modest revenues of approximately $523,000 for the fiscal year ended December 31, 2025, alongside a net loss of about $5.1 million. Its balance sheet as of the same date shows strong liquidity with a current ratio of 8.83 and cash ratio of 6.32, supported by cash, short-term investments, and current assets significantly exceeding current liabilities. In early 2026, iTonic entered a private placement to raise approximately $20 million through issuance of Class A ordinary shares. The company also completed a strategic acquisition of a 51% stake in iTonic Corporation, with equity and warrants issuance tied to performance milestones through 2028. Recent governance updates include director resignations and appointments. Public disclosures provide limited detail on the company’s specific industry focus or product offerings.

Wright Investors Service Holdings, Inc. is a shell company as defined under U.S. securities laws, with nominal operations and no current revenues. The company’s primary assets consist of cash, cash equivalents, and short-term investments in money market mutual funds. The board of directors is actively considering strategic options to deploy these funds, including acquiring interests in operating businesses across various sectors. Until such deployment, the company maintains its liquid assets in high-grade, short-term investments to preserve principal and liquidity. The company has incurred recurring operating losses and negative cash flows, resulting in a net loss of $1,024,000 for the fiscal year ended December 31, 2025. The company’s financial position includes a strong current ratio of 17.44 as of year-end 2025, reflecting a substantial liquidity buffer relative to current liabilities. The company’s stock is traded on the OTC market under the ticker IWSH.

STRATS(SM) Trust for Procter & Gamble Securities, Series 2006-1 operates as a trust issuing synthetic fixed-income securities that derive their value from underlying Procter & Gamble securities. The trust's business model centers on providing investors with fixed-income exposure linked to Procter & Gamble through synthetic instruments. Public disclosures do not include detailed financial or operational metrics, and the trust's sector and industry classifications are not specified. The trust maintains a market price of $24.80 as of March 30, 2026, and has a documented history of scheduled dividend payments.

Thayer Ventures Acquisition Corp II is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands on April 23, 2024. Its business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company completed its Initial Public Offering on May 16, 2025, raising gross proceeds of approximately $201.25 million, which were placed in a Trust Account invested in money market funds. The company has not generated operating revenues and has focused on organizational activities, IPO preparation, and identifying a target for a Business Combination. It earns non-operating income from investments held in the Trust Account and incurs expenses related to public company compliance and due diligence. The company has no long-term debt but has contractual obligations for administrative services. It maintains effective internal controls over financial reporting and does not engage in off-balance sheet financing. The company faces risks related to completing a Business Combination within the required timeframe, which is critical to its continuation as a going concern.

STRATS SM TRUST FOR WAL-MART STORES, INC. SECURITIES, SERIES 2005-4 is a structured trust formed in 2003 that issues certificates backed by securities of Wal-Mart Stores, Inc. The trust is managed by Synthetic Fixed-Income Securities, Inc. as depositor and U.S. Bank Trust National Association as trustee. It regularly distributes income to certificate holders and its certificates trade on the NYSE under the ticker GJO. The trust itself does not disclose operational financials or business segments, and its activities are limited to holding and distributing income from the underlying Wal-Mart securities.

STRATS SM TRUST FOR U S CELL CORP SEC SERIES 2004 6 is a specialized trust formed in 2003 that holds securities issued by United States Cellular Corporation as its sole assets. The Trust issues certificates to investors and distributes income periodically. The Trust's operations are limited to holding and distributing income from these underlying securities, with no independent business activities disclosed. The Trust's certificates trade on the New York Stock Exchange, and the market price was $9.94 as of March 30, 2026.

Neumora Therapeutics, Inc. operates as a clinical-stage biotechnology company developing therapies for central nervous system disorders, including Alzheimer's disease agitation. The company is publicly listed on Nasdaq under the ticker NMRA. It has reported encouraging Phase 1b clinical data for its NMRA-511 candidate and clinically meaningful Phase 1 results, indicating active advancement in its pipeline. Financially, Neumora reported a net loss of $236.93 million for the fiscal year ended December 31, 2025, with strong liquidity metrics including cash and equivalents of $182.53 million and a current ratio of 5.87 as of the same date [S1].

Cytosorbents Corp is a medical technology company specializing in blood purification devices that use biocompatible, highly porous polymer beads to remove harmful substances from blood and other bodily fluids. Its products include CytoSorb, ECOS-300CY, VetResQ, and the PuriFi pump. CytoSorb is approved in the European Union and distributed in over 70 countries to treat critical illnesses characterized by severe inflammation, such as sepsis, COVID-19, trauma, and liver failure. The company is actively pursuing regulatory approvals in the U.S. and Canada for DrugSorb-ATR, a device designed to reduce perioperative bleeding in patients on antithrombotic drugs undergoing cardiac surgery. Cytosorbents has established multiple global distribution and co-marketing agreements with companies such as Fresenius Medical Care AG, Aferetica s.r.l., Terumo Cardiovascular Group, and B. Braun Avitum AG. The company’s business model relies on regulatory approvals, clinical validation, market acceptance, and partnerships to commercialize its products.

PMGC Holdings Inc. operates as a diversified holding company with four wholly owned subsidiaries: Northstrive Biosciences (biopharmaceuticals focusing on engineered probiotics for obesity-related muscle preservation), PMGC Capital LLC (multi-strategy investment firm), Pacific Sun Packaging, Inc. (specialty packaging for sensitive IT hardware components), and AGA Precision Systems LLC (precision CNC machining for aerospace, defense, and industrial sectors). The company divested its skincare business in early 2025 to focus on larger markets and biotechnology assets. Its subsidiaries serve diverse customers including OEMs, contract manufacturers, data center operators, and defense contractors. The company pursues growth through acquisitions and strategic investments, with recent deals expanding its manufacturing footprint and product offerings.

Vor Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases, with telitacicept as a key product candidate. The company has actively raised capital through public and private offerings to fund clinical trials and pre-commercialization efforts. It maintains strong liquidity with over $450 million in cash, equivalents, and short-term investments as of the end of 2025. The company operates under governance structures that include cybersecurity risk oversight by the Board's Audit Committee and management. Vor Biopharma is not currently involved in any material legal proceedings.

Franklin Crypto Trust is a Delaware statutory trust formed in 2024 that offers the Franklin Crypto Index ETF (ticker EZPZ). The Fund passively tracks the CF Institutional Digital Asset Index, which includes a basket of major digital assets weighted by free float market capitalization. The Fund commenced operations on February 20, 2025, and issues shares only to Authorized Participants in Creation Units of 50,000 shares. Shares are listed and traded on the Cboe BZX Exchange. The Fund's digital assets are custodied by Coinbase Custody, with Coinbase Inc. as Prime Broker, and cash is held by The Bank of New York Mellon. The Sponsor is Franklin Holdings, LLC, and Franklin Distributors, LLC acts as the marketing agent. The Fund's NAV is calculated daily based on CF Reference Rates aggregating spot prices from multiple exchanges. The Fund is a passive, non-leveraged vehicle that does not use derivatives. The Sponsor assumes ordinary fees and expenses up to specified limits, while the Fund bears transaction costs related to digital asset trading. The Fund's shares provide investors access to digital assets through traditional brokerage accounts without the need to manage wallets or keys directly.

Kelso Technologies Inc., incorporated in 1987 and headquartered in British Columbia, Canada, is a product engineering company specializing in the research, development, production, and distribution of proprietary equipment for transportation applications. The company primarily manufactures specialized tank car equipment, including safety relief valves, vacuum relief valves, bottom outlet valves, and angle valves, which are critical for the safe handling and transport of hazardous and non-hazardous commodities. Kelso operates through two wholly owned subsidiaries, Kelso Technologies (USA) Inc. and KIQ X Industries Inc., with manufacturing and R&D facilities in Bonham, Texas, and West Kelowna, British Columbia. The company has developed an automated suspension-based Advanced Driver-Assistance System (ADAS) for wilderness terrain vehicles, targeting emergency and commercial applications in challenging environments. Kelso's products emphasize operational safety, economic advantages, and environmental protection. The company maintains a domestic US supply chain to mitigate tariff risks and holds certifications from the Association of American Railroads. Financially, Kelso reported revenues of approximately $10.78 million and net income of $447,397 for fiscal 2025, with a strong liquidity position and no long-term debt. The company is focused on obtaining regulatory approvals for new products and managing costs amid industry cyclicality and macroeconomic pressures.

EUBG is a holding company incorporated in Nevada that conducts its business through subsidiaries in Hong Kong and China. Its primary operating subsidiary in China provides digital marketing consulting and related services aimed at start-up and small-size companies, helping them leverage e-commerce platforms and build brand presence. The company’s services include marketing consultation, digital commerce empowerment, and agency-based sourcing and marketing, often integrated with the Chuangyetianxia APP platform developed by a related party. EUBG’s business model relies on performance-based and fixed-fee arrangements with clients, with a significant portion of revenue generated through the APP platform. The company recently expanded into the fintech sector by acquiring a Hong Kong money lender entity. EUBG faces operational challenges including customer concentration, regulatory compliance in China, and restrictions on cash transfers within its corporate structure.

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates primarily targeting oncology and immunology indications. In February 2026, the company expanded its pipeline by acquiring dual-targeting CAR-T assets, including TPST-2003, an autologous CD19/BCMA CAR-T therapy in clinical development for relapsed or refractory multiple myeloma. The CAR-T portfolio also includes other autologous, allogeneic, and in vivo dual-targeting therapies targeting hematologic malignancies, solid tumors, and immunology diseases such as lupus. The small molecule pipeline features amezalpat, a selective PPARα antagonist for first-line hepatocellular carcinoma, which is Phase 3-ready with regulatory designations, and TPST-1495, a dual EP2/EP4 antagonist planned for Phase 2 study in familial adenomatous polyposis funded by the National Cancer Institute. The company emphasizes a capital-efficient development strategy leveraging partner support and external funding to advance multiple programs while managing internal cash resources. Manufacturing is outsourced to third parties with internal oversight. The company faces competition from large pharmaceutical and biotech firms developing similar therapies but differentiates through its dual-targeting CAR-T architecture and first-in-class small molecules.

Electro-Sensors, Inc. is a Nasdaq-listed company (ticker: ELSE) with recent SEC filings providing financial data through the fiscal year ended December 31, 2025. The company reported positive net income and earnings per share, alongside strong liquidity ratios indicating a solid short-term financial position. Publicly available information includes shareholder meeting outcomes and appointment of auditors. News coverage over recent years has focused on the company's improving returns on capital and valuation considerations, though detailed descriptions of its business model, industry, and product offerings are not disclosed in the available SEC excerpts.

Steele Bancorp Inc is a bank holding company headquartered in Mifflinburg, Pennsylvania, formed by the merger of Mifflinburg Bancorp and Northumberland Bancorp effective August 1, 2025. The company owns Central Penn Bank & Trust, a state-chartered commercial bank with thirteen branches serving four Pennsylvania counties. The bank offers deposit accounts, consumer and commercial loans, residential real estate loans, trust services, and brokerage services through third parties. The company focuses on community banking with local decision-making and personalized service. As of December 31, 2025, Steele Bancorp had $1.26 billion in assets, $918 million in loans, and $1.11 billion in deposits. The company employs 177 people and operates under a single reportable segment. It is regulated by federal and state banking authorities and complies with capital adequacy and other regulatory requirements.

TechCom, Inc. is a shell company with no current operations. Historically, it acquired a Chinese broadband technology company, Beijing Innotrek Technology Co. Ltd, which specialized in network communications and broadband installation services, but this subsidiary is no longer active. The company has undergone several corporate changes including re-domiciling to Delaware and a name change. As of the latest filings, TechCom has no revenue, no research and development expenses, and no intellectual property. The company is seeking a merger target to establish operations but currently faces significant financial and operational challenges.

Gold Fields Limited operates as a global gold mining company with significant operations in Australia, South Africa, Ghana, Peru, and Chile. The company’s financial statements are prepared in U.S. dollars under IFRS standards. It reports various non-IFRS financial measures such as all-in sustaining costs and adjusted free cash flow to provide additional insight into operational efficiency and financial health. The company maintains liquidity with substantial cash reserves and current assets exceeding current liabilities as of the end of 2024. Gold Fields has access to credit facilities and has managed bridge and syndicated loans to support acquisitions and refinancing activities. The company also discloses environmental and regulatory matters and sustainability metrics including greenhouse gas emissions.